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Introduction 
Immunoglobulin G4-related disease (IgG4-RD) is a 
rare, chronic inflammatory disorder characterized 
clinically by tumor-like enlargement of organs and 
histologically by lymphoplasmacytic infiltrate with 
IgG4-positive plasma cells, storiform fibrosis, and 
obliterative phlebitis. The disease can affect multiple 
organs simultaneously or at different times. 
Extracutaneous presentations include swelling of 
the lacrimal and salivary glands (Mikulicz disease), 
chronic sclerosing sialadenitis (Küttner tumor), 
retroperitoneal fibrosis (Ormond disease), type 1 
autoimmune pancreatitis, thyroiditis, aortitis, 
sclerosing cholangitis, pneumonitis, nephritis, and 
lymphadenopathy [1]. 
In 2011, comprehensive diagnostic criteria for IgG4-
RD were introduced to establish guidelines for 
organs such as the skin that lack well-defined, organ-
specific diagnostic criteria [2]. These comprehensive 
diagnostic criteria include: (1) swelling or masses; (2) 
serum IgG4 levels > 135mg/dl; and (3) histology 
showing marked lymphocyte and plasmacyte 
infiltration and fibrosis, >10 IgG4+ plasma cells/high 
powered field, and percentage of IgG4+ plasma 
cells/IgG+ plasma cells >40%. The diagnosis is 
definite when criteria (1), (2), and (3) are fulfilled, 
probable when criteria (1) and (3) are fulfilled, and 
possible when criteria (1) and (2) are fulfilled [2].  
However, the diagnosis of cutaneous IgG4-RD is 
particularly difficult owing to its rare presentation 
and relatively recent recognition in the literature. 
Skin lesions were identified in only 6.3% of cases of 
IgG4-RD in a study of 80 Japanese patients [3],and in 
only 4.2% of cases in a study of 118 Chinese patients 
[4]. By applying the comprehensive diagnostic 
Abstract 
Immunoglobulin G4-related disease (IgG4-RD) is a 
chronic inflammatory condition characterized by 
IgG4+ plasma cell infiltration of the skin and other 
organs. Cutaneous forms of the disease may be 
under recognized owing to poorly defined 
diagnostic criteria and relatively recent recognition in 
the literature. The aim of this review is to describe the 
clinical, histological, and serological presentations of 
cutaneous IgG4-RD, and to provide an overview of its 
systemic manifestations for dermatologists. Cases of 
cutaneous IgG4-RD identified in the literature review 
were compared to control cases. Clinically, plaque 
morphology and systemic involvement of the orbit, 
submandibular gland, lacrimal gland, and parotid 
gland were associated with a diagnosis of cutaneous 
IgG4-RD. Histologically, lymphoplasmacytic infiltrate 
and percentage of IgG4+ plasma cells/IgG+ plasma 
cells > 40% were associated with the diagnosis. 
Serologically, neither elevated serum IgG4 nor IgE 
concentrations were associated with the diagnosis. 
Dermatologists should consider IgG4-RD as part of 
the differential diagnosis for nodules, papules, and 
plaques with an IgG4+ plasma cell infiltrate, 
especially in middle-aged and elderly males with 
systemic manifestations of the disease. Diagnosis 
requires thorough investigation of both cutaneous 
and systemic clinical and histological presentations. 
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criteria to reported cases of cutaneous IgG4-RD in 
the literature, we aim to describe the clinical, 
histological, and serological manifestations of 
cutaneous IgG4-RD. Furthermore, because skin 
presentation rarely occurs in isolation and the skin 
may not be the first system affected by the disease  
[3, 5], we build upon prior reviews by discussing 
systemic manifestations so that dermatologists can 
better suspect and establish a diagnosis of IgG4-RD 
based on the holistic, multi-organ clinical and 
histological presentation. 
Search strategy for systemic IgG4-RD 
Separate searches on PubMed were performed for 
each organ system. Keywords in respective searches 
included: “Mikulicz disease,” “Sjögren syndrome,” 
“Küttner tumor,” “autoimmune pancreatitis,” “IgG4-
RD of the orbit,” “sclerosing cholangitis,” “IgG4-RD of 
the kidney,” “IgG4-RD of the thyroid,” “IgG4-RD of the 
lung,” “retroperitoneal fibrosis,” “IgG4-RD of the 
aorta,” and “IgG4-RD and malignancy.” References 
cited in articles from the initial search were scanned 
for additional articles. 
Search strategy for cutaneous IgG4-RD 
Our methods were derived from a previous review of 
cutaneous IgG4-RD [6]. A search of the literature for 
cutaneous manifestations of IgG4-RD was performed 
using PubMed (Figure 1). Key words included “IgG4-
related disease,” “IgG4-related skin disease,” “IgG4-
related systemic disease,” “IgG4-related sclerosing 
disease,” OR “IgG4” AND “skin,” “dermatology,” 
“dermatologic,” OR “cutaneous.” This initial search 
was supplemented by using the Similar Articles 
feature of PubMed and by scanning reference 
sections of articles from the initial search. Articles 
published in a language other than English, 
published before the year 2000, and focused on 
nonhuman studies were excluded. The following 
sections regarding article selection, data extraction, 
and data analysis apply to cutaneous disease only. 
Article selection 
Articles were screened based on title and abstract. 
Review articles, articles that were irrelevant to IgG4-
RD or its differential diagnosis, articles that lacked 
skin presentation of IgG4-RD, and articles that could 
not be obtained through the library system (a list is 
provided after the Reference section) were excluded 
from full-text assessment. Full text articles that 
lacked sufficient cutaneous data to apply the 
comprehensive diagnostic criteria were excluded [2]. 
Data extraction 
From each full-text article reviewed, the following 
data were extracted: country and year of publication; 
general characteristics of patients (age, sex, 
ethnicity); clinical presentation (location and 
morphology of cutaneous and systemic lesions); 
serum studies (IgG, IgG4, IgE, anti-Ro, anti-La); 
histological analysis of cutaneous lesions 
(description of biopsy with location of infiltrate and 
fibrosis, IgG4+ plasma cells/high power field, 
percentage of IgG4+ plasma cells/IgG+ plasma cells); 
and treatment used and response. The 
comprehensive diagnostic criteria [2] were then used 
to characterize the lesions as cutaneous 
manifestations of IgG4-RD or controls. 
Search strategy for controls 
The differential diagnosis for cutaneous IgG4-RD has 
been described in previous reviews of the disease 
and includes conditions that resemble IgG4-RD 
clinically with erythematous nodules, papules, and 
plaques, and histologically with lymphoplasmacytic 
infiltrate and increased IgG4+ plasma cells [6, 7]. 
Control cases included in our review resulted from 
the same search and article selection as cases of 
cutaneous IgG4-RD (as depicted in Figure 1) and 
were subject to the same data extraction as 
described above. Thus, the controls analyzed in this 
review included Castleman disease, angiolymphoid 
hyperplasia with eosinophilia, cutaneous 
plasmacytosis, and Kimura disease, but did not 
include all conditions that are part of the differential 
diagnosis for cutaneous IgG4-RD. 
Cutaneous IgG4-RD 
Characteristics of included studies 
The initial search for cutaneous IgG4-RD found 440 
articles that were screened based on title and 
abstract (Figure 1). Of these, 67 full text articles were 
reviewed, and 37 articles with sufficient data to apply 
the comprehensive diagnostic criteria to cutaneous 
lesions were included in the data analysis. There 
were 52 cases of cutaneous IgG4-RD [3, 5, 8-38], as 
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well as 23 control cases [35, 39-42]. The 
characteristics of cutaneous IgG4-RD and controls 
are summarized in Table 1. 
Patient characteristics 
The mean age was 60.0 years in cases diagnosed with 
IgG4-RD and 49.3 years in controls, which was 
significantly different between the two groups 
(P<0.001). Male sex comprised 76.9% of IgG4-RD 
cases and 60.1% of controls and was not significantly 
associated with diagnosis (P=0.173).  
Morphology and location 
Among cases with IgG4-RD diagnoses, the majority 
presented with nodules (40.4%), papules (36.5%), 
and plaques (32.7%), though only plaques (P=0.042) 
were significantly associated with IgG4-RD 
diagnosis. Cutaneous lesions were predominantly 
located on the head and neck in IgG4-RD cases 
(73.1%), and were less commonly reported on the 
trunk (38.5%) and extremities (28.9%). Most cases 
associated with IgG4-RD also reported pruritus 
(61.1%).  
Serum studies 
There was no significant difference in serum IgG4 or 
serum IgE between cutaneous IgG4-RD cases and 
controls (P=0.051 and P=0.914, respectively). 
Histology 
In cases with IgG4-RD, lymphoplasmacytic infiltrate 
(90.4%, P=0.038), infiltration in the subcutaneous 
tissue (51.1%, P<0.001), and percentage of IgG4+ 
plasma cells/IgG+ plasma cells >40% (94.2%, 
P<0.001) were significantly associated with the 
diagnosis. The majority of cases with IgG4-RD had 
infiltration in the dermis (86.7%) and many cases 
reported fibrosis (43.5%), but neither was associated 
with diagnosis (P=0.319 and P=0.800, respectively). 
Systemic manifestations with cutaneous IgG4-RD 
Systemic manifestations prior to, subsequent to, 
and/or concurrent with cutaneous presentation 
were found in the majority of IgG4-RD cases (92.5%), 
and systemic involvement was significantly 
associated with diagnosis (P<0.001). Involvement of 
the submandibular gland (30.8%, P=0.002), lacrimal 
gland (30.8%, P=0.002), parotid gland (41.0%, 
P=0.009), and orbit (17.9%, P=0.021) were 
significantly associated with diagnosis. 
The prevalence of systemic manifestations of IgG4-
RD reported in the literature is shown in Table 2. Of 
note, the prevalence of IgG4-RD is poorly established 
and often reported from studies of only single 
populations [4, 43, 44]. Compared to larger studies of 
IgG4-RD, almost all systemic presentations occurred 
less frequently in the cases of cutaneous IgG4-RD 
included in this review. This includes the lacrimal 
gland (30.8% of cutaneous IgG4-RD cases versus 
50.8% reported in the literature), salivary glands 
(58.9% versus 64.6%), pancreas (7.69% versus 38.1%), 
biliary tract (0% versus 17.8%), kidneys (10.3% versus 
24.6%), thyroid (0% versus 1.7%), lung (7.69% versus 
27.1%), retroperitoneum (2.56% versus 26.3%), aorta 
(0% versus 36.3%), and lymph nodes (25.6% versus 
63.5%), [4, 44]. The exception was orbital 
involvement, which was reported in 17.9% of 
cutaneous IgG4-RD cases compared to 17% reported 
in the literature [43]. 
Furthermore, because the lacrimal and salivary 
glands are often involved in Sjögren syndrome (SS),  
 
Figure 1. Search strategy for cutaneous IgG4-related disease 
(RD) and controls. 
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Table 1. The characteristics of cutaneous IgG4-related disease (RD) and controls. 
 
Characteristics    
Mean age, years (SD) 56.7 (12.8) 60.0 (12.1) 49.3 (11.2) <0.001 
Male 54 (72.0) 40 (76.9) 14 (60.1) 0.173 
Clinical Presentation   
Morphology    
Nodule 32 (42.7) 21 (40.4) 11 (47.8) 0.617 
Papule 25 (33.3) 19 (36.5) 6 (26.1) 0.435 
Plaque  19 (25.3) 17 (32.7) 2 (8.70) 0.042 
Other 7 (9.33) 1 (1.92) 6 (26.1) 0.003 
Pruritus 22 (57.9) 22 (61.1) 0 0.171 
Location    
Head/Neck 53 (70.1) 38 (73.1) 15 (65.2) 0.585 
Extremities 24 (32.0) 15 (28.9) 9 (39.1) 0.427 
Trunk 33 (44.0) 20 (38.5) 13 (56.5) 0.207 
Systemic Involvement   
Systemic  43 (68.3) 37 (92.5) 6 (26.1) <0.001 
Lymphadenopathy 15 (24.2) 10 (25.6) 5 (21.7) 1 
Submandibular 12 (19.4) 12 (30.8) 0 0.002 
Lacrimal 12 (19.4) 12 (30.8) 0 0.002 
Orbit  8 (12.9) 7 (17.9) 0 0.021 
Parotid 18 (29.0) 16 (41.0) 2 (8.70) 0.009 
Other 7 (11.2) 7 (17.9) 0 0.04 
Serum Studies    
IgG4, avg mg/dl (SD) 732 (590) 786 (589) 405 (515) 0.051 
IgE, avg IU/dl (SD) 1902 (1721) 1762 (1349) 2440 (2853) 0.914 
Histopathologic   
IgG4/IgG > 40% 46 (70.8) 49 (94.2) 7 (30.4) <0.001 
IgG4/HPF > 10 54 (94.7) 36 (94.7) 18 (94.7) 1 
Lymphoplasmacytic 63 (84.0) 47 (90.4) 16 (69.6) 0.038 
Dermal infiltrate 53 (89.3) 39 (86.7) 14 (100.0) 0.319 
Subcut infiltrate  23 (39.0) 23 (51.1) 0 <0.001 
Fibrosis 29 (42.0) 20 (43.5) 9 (39.1) 0.800 
Therapy    
Systemic steroid 34 (69.4) 29 (74.4) 5 (50.0)  
Skin response  22 (81.5) 22 (81.5) NR  
Systemic response  11 (84.6) 11 (84.6) NR  
Skin relapse 14 (93.3) 14 (93.3) NR  
Systemic relapse  6 (85.7) 6 (85.7) NR  
Other therapy  14 (28.6) 13 (33.3) 1 (7.14)  
Azathioprine 4 (8.16) 4 (10.2) 0  
Rituximab 4 (8.16) 4 (10.2) 0  
Thalidomide 2 (4.08) 2 (5.12) 0  
Surgical resection  3 (6.12) 3 (7.69) 0  
Response to other 13 (92.9)  9 (90.0) 0  
 
“All” denotes cases of IgG4-RD and controls. “IgG4-RD” denotes all cases of definite, probable, or possible IgG4-RD. All values are denoted as: Number 
(percentage), unless otherwise specified. IgG4/IgG > 40% indicates that >40% of IgG+ plasma cells were IgG4+. IgG4/HPF indicates the number of 
IgG4+ plasma cells per high powered field. Skin response to therapy included decrease in size, decrease in number, or resolution of skin lesions. 
Systemic response to therapy included decrease in swelling and/or resolution of symptoms in affected organs. NR = not reported. Cases included in 
analysis are cited in references [3, 5, 8-38], and controls included cases with similar clinical and histological presentation [35, 39-42]. 
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we reviewed whether any cases or controls were 
incorrectly diagnosed with SS. Only one of the 
cutaneous IgG4-RD cases had previously been 
misdiagnosed as SS. Five cases of IgG4-RD (9.61%) 
reported anti-SS-A/Ro and anti-SS-B/La antibody 
testing; all were negative. 
Therapy and response to therapy 
Systemic corticosteroids were used in the majority of 
IgG4-RD cases (74.4%), with 81.5% reporting a 
cutaneous response (decrease in size, decrease in 
number, or resolution of skin lesions) and 84.6% 
reporting a systemic response (decrease in swelling 
and/or resolution of symptoms in affected organs). 
Upon taper or discontinuation of systemic 
corticosteroids, 93.3% of IgG4-RD cases reported 
relapse of skin lesions and 85.6% reported relapse of 
systemic symptoms. Other therapies used for 
cutaneous IgG4-RD either alone or in combination 
with corticosteroids included azathioprine in 10.2% 
of cases, with response in 25.0%; rituximab in 10.2% 
of cases, with response in 100.0%; thalidomide in 
5.12% of cases, with response in 100.0%; and surgical 
resection in 7.69% of cases, with response in 100.0%. 
Systemic IgG4-RD  
The prevalence, clinical, and histological characteristics 
of systemic IgG4-RD are summarized in Table 2. 
Lacrimal, parotid, and submandibular glands: Mikulicz 
disease and Küttner tumor 
Mikulicz disease (MD) presents with persistent, 
symmetrical, and painless enlargement of the 
lacrimal, parotid, and/or submandibular glands. 
Clinically, patients can have dry eyes and dry mouth 
and histologically, glands show lymphoplasmacytic 
infiltrate with fibrosis [45, 46]. 
Although Mikulicz disease and Sjögren syndrome 
have similar presentations, there are several clinical, 
serological, histological, radiological, and 
therapeutic factors that distinguish the two diseases. 
Clinically, the incidence of xerostomia, xeropthalmia, 
and arthralgia are significantly lower in Mikulicz 
disease versus SS, but allergic rhinitis and 
autoimmune pancreatitis (discussed below) are 
more frequently associated with Mikulicz disease 
[47]. Serologically, rheumatoid factor, antinuclear 
antibody, antiSS-A/Ro, and antiSS-B/La antibodies 
were significantly lower in Mikulicz disease 
compared to SS, but IgG, IgG4, and IgE levels are 
higher in Mikulicz disease [47]. Histologically, only 
Mikulicz disease shows marked infiltration of IgG4+ 
plasma cells and Sjögren syndrome is associated 
with more cell apoptosis [46-49]. Radiologically, only 
Sjögren syndrome demonstrates the “apple-tree 
sign” on sialography, indicative of contrast spilling 
from degenerated glands [46]. Therapeutically 
Mikulicz disease can regain salivary function after 
corticosteroids, whereas Sjögren syndrome does not 
[46, 47]. 
Küttner tumor, or chronic sclerosing sialadenitis, 
presents with asymmetrical and firm swelling of the 
salivary gland, most often of the submandibular 
gland. It can be painful or asymptomatic and 
histology can show lymphoplasmacytic infiltrate, 
storiform fibrosis, and/or obliterative phlebitis [50].  
Orbit 
Immunoglobulin G4-RD of the orbit presents with 
swelling of the lacrimal gland, soft tissue, extraocular 
muscles, palpebrae, optical nerve, or orbital bone, 
but typically spares the conjunctiva [43]. Although 
vision loss is uncommon, swelling can lead to 
proptosis and compression of local nerves [51]. 
Histologically, there is lymphoplasmacytic infiltrate, 
fibrosis and lymphoid follicle formation, but 
characteristic obliterative phlebitis is less common 
[43, 52]. 
Pancreas: autoimmune pancreatitis 
Autoimmune pancreatitis (AIP) associated with IgG4-
RD presents most commonly in elderly males and 
may be asymptomatic or present with mild 
abdominal symptoms and obstructive jaundice. 
Eventually, some patients lose endocrine function of 
the pancreas and can develop secondary diabetes 
[53]. Histologically, AIP typically has the 
characteristic triad associated with IgG4-RD: 
lymphoplasmacytic infiltrate, storiform fibrosis, and 
obliterative phlebitis [54, 55]. Imaging with CT or MRI 
shows diffuse, segmental, or focal enlargement of 
the pancreas with a low-density rim [54]. 
Biliary ducts: sclerosing cholangitis 
Sclerosing cholangitis often presents concurrently 
with AIP. It can be asymptomatic or present with 
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obstructive jaundice, abdominal pain, weight loss, 
and/or steatorrhea [56]. Histologically, it also 
presents with the characteristic triad associated with 
IgG4-RD [56]. Imaging most often shows obstruction 
of the lower common bile duct [57]. The condition 
can be difficult to distinguish from primary 
sclerosing cholangitis (PSC). However, IgG4-RD has 
elevated serum IgG4 whereas PSC does not, and PSC 
is more often associated with inflammatory bowel 
disease [57]. IgG4-RD sclerosing cholangitis can also 
be confused with cholangiocarcinoma, but the latter 
has higher serum bilirubin and CA19-9 [58]. 
Kidney: tubulointerstitial nephritis and membranous 
nephropathy 
Kidney disease associated with IgG4-RD is often 
detected through abnormal urinary analysis, 
radiological studies, or kidney function tests 
obtained during workup of extrarenal symptoms 
[59]. Renal involvement includes tubulointerstitial 
nephritis (TIN) and membranous nephropathy. 
Histology of TIN shows lymphoplasmacytic infiltrate, 
fibrosis, and tubular atrophy; CT imaging shows 
enlarged kidneys and hypodense lesions [59]. Unlike 
other manifestations of IgG4-RD, TIN is associated 
with hypocomplementemia [59]. Membranous 
nephropathy can be concurrent with TIN and 
presents with nephrotic range proteinuria and 
hypoalbuminemia [60].  
Thyroid 
Reidel thyroiditis is an inflammatory condition 
characterized by fibrosis of the thyroid gland leading 
to destruction of the tissue and invasion into 
adjacent structures. A relationship between Reidel 
thyroiditis and IgG4-RD has been proposed based on 
shared features including lymphoplasmacytic 
infiltrate, obliterative phlebitis, tissue eosinophilia, 
and fibrosis [61].  
A fibrosing variant of Hashimoto thyroiditis has also 
been associated with IgG4-RD [62]. In comparison to 
IgG4-negative thyroiditis, IgG4-RD thyroiditis 
presents serologically with higher levels of anti-
thyroglobulin and anti-thyroid peroxidase 
antibodies [63], radiologically with diffuse low 
echogenicity on ultrasound [63], and histologically 
with dense infiltrate of IgG4+ plasma cells [63, 64]. 
Lung 
Immunoglobulin G4-RD of the lung has a diverse 
clinical presentation; it can present with cough, 
dyspnea, and chest pain, or without symptoms. The 
disease is divided into four radiological subtypes: 
solid nodular, bronchovascular, alveolar interstitial, 
and round-shaped ground glass opacity [65]. 
Histologically, there is lymphoplasmacytic infiltrate 
in all subtypes, but obliterative phlebitis is more 
common in the solid nodular type [65, 66]. The solid 
nodular type may be confused with sarcoidosis, but 
IgG4-RD is not associated with elevated angiotensin 
converting enzyme (ACE) levels [65].  
Retroperitoneal fibrosis 
Retroperitoneal fibrosis, historically known as 
Ormond disease, presents with a retroperitoneal 
mass that can lead to hydronephrosis, flank pain, 
and/or back pain [67]. Histologically, it displays the 
same classic triad found in AIP and sclerosing 
cholangitis: lymphoplasmacytic infiltrate, storiform 
fibrosis, and obliterative phlebitis [67, 68]. IgG4-
related retroperitoneal fibrosis must be 
distinguished from secondary causes of 
retroperitoneal fibrosis, such as malignancy, 
infections, and radiation therapy. 
Aortitis 
IgG4-RD is associated with inflammatory abdominal 
aortic aneurysms, which may present with 
abdominal and lower back pain [69]. IgG4-RD aortitis 
and periaortitis most often involve the infra-renal 
aorta and can extend into the iliac arteries and 
periaortic tissue [44]. Histologically, there is 
obliterative phlebitis, lymph follicle formation, and 
eosinophilia [69, 70]. Thoracic aortitis can lead to 
aneurysm formation or dissection, though it is often 
asymptomatic and detected only by imaging [70].  
Lymphadenopathy 
Lymphadenopathy associated with IgG4-RD can be 
generalized or localized to disease-affected organs. 
Typically, the nodes swell to less than 2cm and 
patients remain afebrile [71]. Histologically, most 
nodes do not have storiform fibrosis, but rather fall 
within five morphological subtypes: Castleman 
disease-like, reactive follicular hyperplasia, 
interfollicular plasmacytosis and immunoblastosis, 
progressive transformation of germinal center-like, 
Volume 25 Number 6| June 2019| 
25(6):1 
 
 
- 7 - 
Dermatology Online Journal  ||  Review 
and inflammatory pseudotumor-like morphologies 
[72]. Although lymphadenopathy is common, biopsy 
is not typically used to establish the diagnosis of 
IgG4-RD because of the histological diversity of 
affected nodes. 
Prognosis 
The prognosis of IgG4-RD depends on the organs 
involved and the severity of fibrosis. There can be 
irreversible fibrosis of vital organs including the 
biliary tree, aorta, and retroperitoneum if 
undetected, but asymptomatic lymphadenopathy or 
mild submandibular enlargement may be relatively 
benign. In general, affected organs respond to 
corticosteroids. Although there have been no 
randomized controlled trials for treatment of the 
disease, a general consensus supports 
corticosteroids as first-line therapy to induce 
remission and lower-dose maintenance therapy to 
prevent relapse when necessary [73]. 
Studies examining the relationship of IgG4-RD with 
malignancy have conflicting results. Some studies 
have found an increased risk of malignancy 
associated with IgG4-RD compared to the general 
population [74, 75], whereas others have not [76]. 
Interestingly, one study found that history of 
malignancy increases subsequent risk of IgG4-RD 
[77].  
 
Discussion 
Our review found that cutaneous IgG4-RD most 
commonly presented with pruritic nodules, papules, 
and plaques in middle-aged or elderly male patients 
with systemic forms of the disease, and histologically 
with lymphoplasmacytic infiltrate and percentage of 
IgG4+ plasma cells/IgG+ plasma cells >40%. 
However, not all these characteristics are specific to 
cutaneous IgG4-RD and dermatologists should be 
aware that diagnosis requires clinical and 
histological evaluation of both the skin and systemic 
organs in order to distinguish the disease from 
similar conditions. 
Specifically, Kimura disease presents with 
lymphadenopathy and subcutaneous nodules of the 
head and neck region and can also have abundant 
IgG4+ plasma cell infiltration. It can be distinguished 
from IgG4-RD histologically by reactive vascular 
proliferation and eosinophilic microabscesses in 
lymph nodes. Clinically, Kimura disease typically 
affects younger patients (median age of 44.5 in one 
study) compared to IgG4-RD and rarely affects 
organs such as the pancreas [41]. Other conditions, 
such as pemphigus vulgaris, can also have cutaneous 
lesions with a percentage of IgG4+ plasma cells/IgG+ 
plasma cells > 40% [78]. Thus, although skin biopsy is 
an important factor in diagnosis of cutaneous IgG4-
RD, it should not be used in isolation.  
Similarly, despite the inclusion of elevated serum 
IgG4 (>135mg/dl) as part of the comprehensive 
diagnostic criteria for IgG4-RD, its specificity and 
reliability for diagnosis are debated. We did not find 
a significant difference in serum IgG4 between cases 
and controls. This result is not surprising; serum IgG4 
can be elevated in many other conditions, including 
recurrent infection, systemic autoimmune 
conditions, and unrelated disease of the lungs, biliary 
tract, pancreas, liver, and vasculature [79, 80]. 
Our review also found that systemic IgG4-RD, 
particularly of the orbit and submandibular, lacrimal, 
and parotid glands, was associated with a cutaneous 
IgG4-RD diagnosis. Our results support those from 
previous reviews showing an association between 
cutaneous IgG4-RD diagnosis and systemic 
involvement of the head and neck [6, 7]. For this 
reason, it is important to understand why Mikulicz 
disease is considered a systemic manifestation of 
IgG4-RD rather than a subtype of Sjögren syndrome. 
Mikulicz disease has increased serum IgG, IgG4, and 
IgE, dense IgG4+ plasma cell infiltrate, and 
therapeutic response to corticosteroids, whereas 
Sjögren syndrome does not; Sjögren syndrome is 
associated with increased rheumatoid factor, 
antinuclear antibody, anti-SSA/Ro, and anti-SS-B/La 
antibodies, increased apoptotic cells on histology, 
and demonstrates the “apple tree sign” on 
sialography, features that are not found in Mikulicz 
disease [46, 47, 49]. One possible explanation for 
these histologic, radiologic, and therapeutic 
differences is that lymphocytic infiltration in SS, but 
not in Mikulicz disease, is associated with 
autoimmune-mediated glandular destruction. 
Acinar cells in lacrimal glands affected by Sjögren  
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syndrome have demonstrated much greater 
expression of proteins associated with apoptosis, 
including APO2.7, FasL, and Fas compared to acinar 
cells affected by Mikulicz disease [49]. This may 
explain the lack of functional improvement despite 
corticosteroid therapy in Sjögren syndrome[46, 47]. 
Recognizing systemic forms of the disease discussed 
in our review can help dermatologists suspect the 
diagnosis of cutaneous IgG4-RD and understand its 
prognosis based on the comprehensive, multi-organ 
presentation. However, there are limitations to our 
review; because extracutaneous involvement of 
IgG4-RD can occur after cutaneous presentation, the 
cases we included may have excluded 
manifestations of disease that occurred after 
publication. Furthermore, our sample size is small 
and larger analyses of cutaneous and systemic IgG4-
RD are necessary to fully characterize the disease and 
establish diagnostic criteria for the skin. However, 
our review may help alert dermatologists to this rare 
disease that requires thorough, multi-disciplinary 
clinical and histological evaluation. 
 
Conclusion 
Diagnosis of IgG4-RD is difficult, especially in organs 
such as the skin that lack well-established diagnostic 
criteria. It requires integration of both cutaneous and 
systemic presentations. Dermatologists should 
consider IgG4-RD as part of the differential diagnosis 
for nodules, papules, and plaques with IgG4+ plasma 
cell infiltrate, especially in middle-aged and elderly 
male patients with systemic manifestations of the 
disease involving the orbit, lacrimal glands, and 
salivary glands. 
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Table 2. Overview of the clinical presentation, histology, and differential diagnosis for systemic forms of IgG4-related disease (RD). 
 
Systemic Location  Clinical Presentation Histology Differential Diagnosis References
Lacrimal, Parotid, and 
Submandibular glands 
Prevalence [4]: Dacryoadenitis: 
50.8% Sialadenitis: 64.4% 
Mikulicz Disease: Persistent, 
symmetrical, painless 
enlargement of at least 2 
glands: lacrimal, parotid, or 
submandibular. Dry eyes, dry 
mouth.  
Lymphoplasmacytic 
infiltrate, storiform fibrosis, 
obliterative phlebitis (but 
not often found in parotid) 
Sjögren Syndrome [45−49] 
 
Küttner tumor: Firm mass in 
the submandibular gland. 
Asymptomatic or painful 
Lymphoplasmacytic 
infiltrate, storiform fibrosis, 
lymphoid follicles, 
obliterative phlebitis 
sometimes present
Sjögren Syndrome, 
salivary tumor  [50] 
Orbit 
Prevalence [43]: 17% 
Swelling that can lead to 
proptosis and can compress 
nerves. Can involve the 
lacrimal gland, soft tissue, 
extraocular muscles and 
nerves. Visual impairment is 
uncommon  
Lymphoplasmacytic 
infiltrate, lymphoid follicle 
formation, patternless 
fibrosis. Obliterative 
phlebitis and storiform 
fibrosis uncommon  
MALT lymphoma, 
follicular lymphoma, 
diffuse large B-cell 
lymphoma  
[43, 51, 52] 
Autoimmune pancreatitis 
Prevalence [4]: 38.1% 
Mostly in elderly males, mild 
abdominal symptoms, no 
acute attacks of pancreatitis, 
occasional obstructive 
jaundice. Can have secondary 
loss of endocrine function 
(diabetes).  
Lymphoplasmacytic 
infiltrate, storiform fibrosis, 
obliterative phlebitis  
Type 2 AIP, pancreatic 
head cancer, 
cholangiocarcinoma  
[53−55] 
Sclerosing cholangitis 
Prevalence [4]: 17.8% 
Abrupt obstructive jaundice, 
weight loss, abdominal 
discomfort, often associated 
with autoimmune 
pancreatitis 
Lymphoplasmacytic 
infiltrate, storiform fibrosis, 
obliterative phlebitis  
Primary sclerosing 
cholangitis, 
cholangiocarcinoma 
[56 −58] 
Kidney disease 
Prevalence [4]: 24.6% 
Tubulointerstitial nephritis: 
Commonly detected from 
abnormal urinary analysis, 
renal dysfunction, or 
radiographic abnormalities 
detected from workup for 
extrarenal manifestations. 
Hypocomplementemia 
Lymphoplasmacytic 
infiltrate, eosinophils, 
fibrosis, tubular atrophy. 
Obliterative phlebitis is 
rare.  
ANCA-associated 
vasculitis, Rosai-Dorfman 
disease, Castleman 
disease  
[59] 
Membranous nephropathy: 
Nephrotic range proteinuria.  
Subepithelial deposits in a 
membranous pattern 
 [60] 
Thyroid disease 
Prevalence [4]: 1.7% 
Reidel thyroiditis: Growing 
thyroid mass, can compress 
local structures resulting in 
dyspnea, dysphagia, 
hoarseness, cough.  
Lymphoplasmacytic 
infiltrate, fibrosis with 
destruction of thyroid 
architecture, obliterative 
phlebitis  
Non IgG4-related Reidel 
thyroiditis  [61] 
 
Fibrous variant of 
Hashimoto thyroiditis: 
Hypothyroidism 
Lymphoplasmacytic 
infiltrate, fibrosis, follicular 
degeneration, lymph 
follicle formation
Non IgG4-related 
Hashimoto thyroiditis [62−64] 
Lung disease 
Prevalence [4]: 27.1% 
Asymptomatic or cough, 
dyspnea, chest pain. 
Radiologically: can be solid 
nodular, bronchovascular, 
Diffuse 
lymphoplasmacytic 
infiltration in all 
presentations, but 
Sarcoidosis, Castleman 
disease, lung cancer  [65, 66] 
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alveolar interstitial, or round-
shaped ground glass opacity  
irregular fibrosis and 
obliterative phlebitis more 
common in solid nodular 
type 
Retroperitoneal fibrosis  
Prevalence [4]: 26.3% 
(retroperitoneal fibrosis or 
periaortitis)  
Retroperitoneal mass, can 
have hydronephrosis, flank 
pain, back pain.  
Lymphoplasmacytic 
infiltrate, storiform fibrosis, 
eosinophilia, sometimes 
obliterative phlebitis.  
Idiopathic, secondary 
causes (drug exposure, 
infection, malignancy)  
[67, 68] 
Aortitis/Periaortitis 
Prevalence [44]: 36.3% 
Abdominal aorta: may have 
poorly localized abdominal, 
back, or thigh pain. Usually 
localized to the infrarenal 
portion and continues to the 
iliacs, can have aneurysm 
formation. Thoracic aorta: 
often asymptomatic, 
aneurysm or dissection. Can 
have saccular formation, 
fibrous adhesion to 
surrounding tissue  
Lymphoplasmacytic 
infiltrate, irregular fibrosis, 
sometimes eosinophilia 
and obliterative phlebitis.  
Other noninfectious 
inflammatory aortitis 
(Takayasu, ANCA-
associated vasculitis)  
[44, 69, 70] 
Lymphadenopathy 
Prevalence [4]: 65.3% 
Regional swelling (around 
other organs affected) or 
systemic. Typically no larger 
than 2 cm. Lacks fever and B 
symptoms 
Castleman disease-like, 
reactive follicular 
hyperplasia, interfollicular 
plasmacytosis and 
immunoblastosis, 
progressive 
transformation of germinal 
center-like, inflammatory 
pseudotumor-like. Often 
lack storiform fibrosis and 
obliterative phlebitis 
Castleman disease, 
lymphoma, other 
malignancies  
[71, 72] 
 
AIP, autoimmune pancreatitis; ANCA, antineutrophil cytoplasmic antibody; MALT, mucosa-associated lymphoid tissue. 
 
 
